Clinical Trial Update: Fingolimod -Response According to Coping - Evaluation [Phase 4]

View source ↗

Summary

Phase 4 clinical trial evaluating Fingolimod response according to coping strategies in relapsing-remitting multiple sclerosis has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Relapsing-remitting Multiple Sclerosis

Drugs mentioned

• Fingolimod (fingolimod)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Multiple Sclerosis, Relapsing-Remitting | Phase 4 | Status: COMPLETED